Replacement sheet 34

CLAIMS

1. Use of a linear or cyclic polymetaphosphate or a soluble salt thereof for the preparation of an intra-articular injectable medicament for the treatment of articular pathologies.

2. Use according to claim 1 wherein the soluble salt is the sodic salt.

3. Use according to claim 1 wherein the polymetaphosphate is included in the following group: polymeric metaphosphate (SMP); tripolymetaphosphate (PSTP); cyclic trimetaphosphate (TSMP), cyclic hexametaphosphate (SEMP).

4. Use according to claim 1 wherein the medicament further comprises effective amounts of anti-oxidants and/or anti-radicals of oxygen and hypochlorite anion.

5. Use according to claim 4 wherein the anti-oxidants are included in the following group: mannitol, vitamin E, vitamin C, carotenoids, tocopherol, taurine, glucosamine sulfate, glucosamine hydrochloride.

6. Use according to any of the previous claims, wherein the medicament further comprises at least one scavenger substance with anti-radical activity.

7. Use according to claim 1 wherein the articular pathology is characterized by calcium pyrophosphate dehydrate (CPPD) and/or hydroxyapatite HAP intra-articular deposits.

8. Use according to claim 1 wherein the medicament has an antioxydant activity.

9. A soluble pharmaceutical composition comprising pharmaceutically effective amounts of cyclic sodium hexametaphosphate or polymeric sodium metaphosphate, mannitol and taurine.

10. Composition according to claim 9 in which the amount of cyclic sodium hexametaphosphate or polymeric sodium metaphosphate is at least 0.5 % (w/v).

11. Composition according to claim 9 in which the amount of mannitol is 1.55 % (w/v).

12. Composition according to claim 9 in which the amount of taurine is 0.3 % (w/v).

13. A soluble pharmaceutical composition comprising pharmaceutically effective amounts of cyclic sodium hexametaphosphate or polymeric sodium metaphosphate, mannitol and glucosamine sulfate.

14. Composition according to claim 13 in which the amount of cyclic sodium hexametaphosphate or polymeric sodium metaphosphate is 0.5 % (w/v).

15. Composition according to claim 13 in which the amount of mannitol is 3.17 % (w/v).

16. Composition according to claim 13 in which the amount of glucosamine sulfate is 0.4 % (w/v).

17. A soluble pharmaceutical composition comprising pharmaceutically effective amounts of cyclic sodium hexametaphosphate or polymeric sodium metaphosphate and glucosamine sulfate.

18. Composition according to claim 17 in which the amount of cyclic sodium hexametaphosphate or polymeric sodium metaphosphate is 0.75 % (w/v).

19. Composition according to claim 17 in which the amount of glucosamine sulfate is 2.2 % (w/v).

20. A pharmaceutical intra-articularly injectable formulation comprising a first container, containing the substance according to claims 1 to 3 in powder form, and a second container containing a solution of diluent in which at least one substance with anti-radical action and/or a substance with anti-oxidant action is dissolved, and wherein the substance of the first container is dissolved before use.

21. An injectable pharmaceutical formulation to be used for continuous washing of an articulation comprising a first container, containing the substance according to claims 1 to 3 in powder form, and a second container containing a solution of diluent in which at least one substance with anti-radical action and/or a substance with anti-oxidant action is dissolved, and in which the composition of the first container is dissolved before use.

22. A pharmaceutical containment formulation to be used after the solubilization of CPPD or HAP crystals in an articulation comprising a container containing a solution of diluent intra-articularly injectable, slightly hypotonic, in which is dissolved at least one substance with anti-radical action of oxygen and anti-hypochlorite anion.

23. Aqueous hypotonic solution in which the substance according to claims 1 to 6 is dissolved.